Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 5/20 | 0.51 |
| ▸ | CTSK | P43235 | 4/20 | 0.51 |
| ▸ | CTSB | P07858 | 2/20 | 0.51 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | AKT1 | P31749 | 3/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6874791 | 1.00 | ATM (0.53) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL29847901 | 0.89 | CTSS (0.58) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL23721718 | 0.89 | CTSS (0.58) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL13109024 | 0.88 | ATM (0.54) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL7408378 | 0.88 | ATM (0.54) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL6835510 | 0.88 | ATM (0.54) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL12166523 | 0.87 | ATM (0.51) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL21609302 | 0.87 | CTSL (0.57) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL12295159 | 0.86 | ATM (0.53) | ATMSYKCTSSCTSKCTSB | |
| SCHEMBL18748463 | 0.86 | ATM (0.53) | ATMSYKCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | SPERO THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | SPERO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| CN-118878638-A | Polymyxin compound, pharmaceutical composition and application thereof | 云顶新耀医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| CN-112789287-B | Compounds of formula (I) | 云顶新耀医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-4316504-A2 | COMPOUNDS | Spero Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| EP-3810633-B1 | COMPOUNDS | SPERO THERAPEUTICS INC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3810633-B1 | COMPOUNDS | SPERO THERAPEUTICS INC (US) | 2023-12-13 | — | — | EP | disclosed |
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-11459357-B2 | Polymyxin compounds | SPERO THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
| CN-112789287-A | Compound (I) | 斯佩罗治疗公司 | 2021-05-11 | — | — | CN | disclosed |
| EP-3810633-A1 | COMPOUNDS | Spero Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| WO-2020002325-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020002325-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528837-B2 | Aryl substituted polymyxin derivatives | PTMS, PNISR, BCAT2 | ATM 91/4885SYK 107/4885CTSS 4094/4885 |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | PTMS, FPR1, BCAT2 | ATM 773/4885SYK 90/4885CTSS 4743/4885 |
| US-20230012121-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPL21 | ATM 1094/4885SYK 910/4885CTSS 2308/4885 |
| US-11459357-B2 | Polymyxin compounds | MRPL37, MRPS18A, PNISR | ATM 1295/4885SYK 817/4885CTSS 2840/4885 |
| US-20210246169-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPS35 | ATM 922/4885SYK 893/4885CTSS 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.